Oxygen Supplementation, Delivery, and Physiologic Effects

  • Stacey Peterson-CarmichaelEmail author
  • Ira Cheifetz
  • Laurent Storme


The delivery of oxygen is a vital component of patient care within pediatric and neonatal intensive care units. Clinicians are constantly altering the support provided to each patient in an attempt to optimize oxygen delivery as defined by the following equation:
$$ {\mathrm{DO}}_2=CO\times \mathrm{arterial}\ {\mathrm{O}}_2\mathrm{content} $$
$$ \mathrm{arterial}\ {\mathrm{O}}_2\mathrm{content}=\left({SaO}_2\ \mathrm{saturation}\times 1.39\ \left(\mathrm{mL}/\mathrm{g}\right)\times Hb\right)+\left(0.003\times {PaO}_2\right) $$
where DO2 represents oxygen delivery; CO, cardiac output; SaO2, arterial oxygen saturation; Hb, hemoglobin; and PaO2, partial pressure of oxygen in arterial blood. Thus, decreased oxygen delivery can result from inadequate cardiac output, low arterial oxygen saturation, inadequate hemoglobin concentration, or low PaO2 as a minor contributor (secondary to the factor of 0.003 in the formula outlined above). In this chapter, we will review the variety of mechanisms by which clinicians can improve the supply of oxygen to the patient to meet the metabolic demands involved with various pathophysiologic processes.


Vascular Endothelial Growth Factor Pulmonary Hypertension Pulmonary Arterial Hypertension Neonatal Intensive Care Unit Oxygen Delivery 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. Atz AM, Lefler AK, Fairbrother DL, Uber WE, Bradley SM (2002) Sildenafil augments the effect of inhaled nitric oxide for postoperative pulmonary hypertensive crises. J Thorac Cardiovasc Surg 124(3):628–629PubMedCrossRefGoogle Scholar
  2. Barst RJ, Maislin G, Fishman AP (1999) Vasodilator therapy for primary pulmonary hypertension in children. Circulation 99(9):1197–1208PubMedCrossRefGoogle Scholar
  3. Benditt JO (2006) The neuromuscular respiratory system: physiology, pathophysiology, and a respiratory care approach to patients. Respir Care 51(8):829–837; discussion 837–9PubMedGoogle Scholar
  4. Connor KM, SanGiovanni JP, Lofqvist C, Aderman CM, Chen J, Higuchi A, Hong S, Pravda EA, Majchrzak S, Carper D, Hellstrom A, Kang JX, Chew EY, Salem N Jr, Serhan CN, Smith LE (2007) Increased dietary intake of ω-3-polyunsaturated fatty acids reduces pathological retinal angiogenesis. Nat Med 13:868–873PubMedCrossRefGoogle Scholar
  5. Cunningham S, Fleck BW, Elston RA, McIntosh N (1995) Transcutaneous oxygen levels in retinopathy of prematurity. Lancet 346:1464–1465PubMedCrossRefGoogle Scholar
  6. Darlow B, Hutchinson J, Henderson-Smart D, Donoghue D, Simpson J, Evans N (2005) Prenatal risk factors for severe retinopathy of prematurity among very preterm infants of the Australian and New Zealand Neonatal Network. Pediatrics 115:990–996PubMedCrossRefGoogle Scholar
  7. Di Fiore JM, Bloom JN, Orge F, Schutt A, Schluchter M, Cheruvu VK, Walsh M, Finer N, Martin RJ (2010) A higher incidence of intermittent hypoxemic episodes is associated with severe retinopathy of prematurity. J Pediatr 157(1):69–73PubMedCrossRefGoogle Scholar
  8. Ghofrani HA, Wiedemann R, Rose F, Schermuly RT, Olschewski H, Weissmann N, Gunther A, Walmrath D, Seeger W, Grimminger F (2002) Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial. Lancet 360(9337):895–900PubMedCrossRefGoogle Scholar
  9. Good WV (2004) Early treatment for retinopathy of prematurity cooperative group. Final results of the early treatment for retinopathy of prematurity (ETROP) randomized trial. Trans Am Ophthalmol Soc 102:233–250PubMedCentralPubMedGoogle Scholar
  10. Holmstrom G, van Wijngaarden P, Coster DJ, Williams KA (2007) Genetic susceptibility to retinopathy of prematurity: the evidence from clinical and experimental animal studies. Br J Ophthalmol 91:1704–1708PubMedCentralPubMedCrossRefGoogle Scholar
  11. Hubbard GB 3rd (2008) Surgical management of retinopathy of prematurity. Curr Opin Ophthalmol 19:384–390PubMedCentralPubMedCrossRefGoogle Scholar
  12. Humbert M et al (2004) Treatment of pulmonary arterial hypertension. NEJM 351(14):1425–1436PubMedCrossRefGoogle Scholar
  13. Ivy DD, Doran AK, Smith KJ, Mallory GB Jr, Beghetti M, Barst RJ, Brady D, Law Y, Parker D, Claussen L, Abman SH (2008) Short- and long-term effects of inhaled iloprost therapy in children with pulmonary arterial hypertension. J Am Coll Cardiol 51(2):161–169PubMedCentralPubMedCrossRefGoogle Scholar
  14. Kong L, Mintz-Hittner HA, Penland RL, Kretzer FL, Chévez-Barrios P (2008) Intravitreous bevacizumab as anti-vascular endothelial growth factor therapy for retinopathy of prematurity: a morphologic study. Arch Ophthalmol 126:1161–1163PubMedCrossRefGoogle Scholar
  15. Kubicka ZJ, Limauro J, Darnall RA (2008) Heated, humidified high-flow nasal cannula therapy: yet another way to deliver continuous positive airway pressure? Pediatrics 121(1):82–88PubMedCrossRefGoogle Scholar
  16. Namachivayam P, Theilen U, Butt WW, Cooper SM, Penny DJ, Shekerdemian LS (2006) Sildenafil prevents rebound pulmonary hypertension after withdrawal of nitric oxide in children. Am J Respir Crit Care Med 174:1042–1047PubMedCrossRefGoogle Scholar
  17. Nichols DG (2008) Rogers’ textbook of pediatric intensive care, 4th edn. Lippincott Williams & Wilkins, PhiladelphiaGoogle Scholar
  18. Olschewski H, Simonneau G, Galiè N, Higenbottam T, Naeije R, Rubin LJ, Nikkho S, Speich R, Hoeper MM, Behr J, Winkler J, Sitbon O, Popov W, Ghofrani HA, Manes A, Kiely DG, Ewert R, Meyer A, Corris PA, Delcroix M, Gomez-Sanchez M, Siedentop H, Seeger W (2002) Aerosolized iloprost randomized study group. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 347(5):322–329PubMedCrossRefGoogle Scholar
  19. Penn JS, Henry MM, Tolman BL (1994) Exposure to alternating hypoxia and hyperoxia causes severe proliferative retinopathy in the newborn rat. Pediatr Res 36:724–731PubMedCrossRefGoogle Scholar
  20. Phelps DL (1992) Retinopathy of prematurity. N Engl J Med 326:1078–1080PubMedCrossRefGoogle Scholar
  21. Phillipson E, Duffin J (2005) Hypoventilation and hyperventilation syndromes, 4th edn. Elsevier/Saunders, PhiladelphiaGoogle Scholar
  22. Polkey MI, Moxham J (2001) Clinical aspects of respiratory muscle dysfunction in the critically Ill. Chest 119(3):926–939PubMedCrossRefGoogle Scholar
  23. Rubin LJ, Rich S (1997) Medical management. In: Rubin L, Rich S (eds) Primary pulmonary hypertension. Marcel Dekker, New YorkGoogle Scholar
  24. Schulze-Neick I, Hartenstein P, Li J, Stiller B, Nagdyman N, Hübler M, Butrous G, Petros A, Lange P, Redington AN (2003) Intravenous sildenafil is a potent pulmonary vasodilator in children with congenital heart disease. Circulation 108(Suppl 1):II167–II173PubMedGoogle Scholar
  25. Sears JE, Pietz J, Sonnie C, Dolcini D, Hoppe G (2009) A change in oxygenation supplementation can decrease the incidence of ROP. Ophthalmology 116:513–518PubMedCrossRefGoogle Scholar
  26. Section on Ophthalmology, American Academy of Pediatrics, American Academy of Ophthalmology, American Association for Pediatric Ophthalmology and Strabismus (2006) Screening examination of premature infants for retinopathy of prematurity. Pediatrics 117:572–576CrossRefGoogle Scholar
  27. Sitbon O, Humbert M, Nunes H, Parent F, Garcia G, Hervé P, Rainisio M, Simonneau G (2002) Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol 40(4):780–788PubMedCrossRefGoogle Scholar
  28. Slonim A, Pollack M (2006) Pediatric critical care medicine, 1st edn. Lippincott Williams & Wilkins, PhiladelphiaGoogle Scholar
  29. SUPPORT Study Group of the Eunice Kennedy Shriver NICHD Neonatal Research Network (2010) Target ranges of oxygen saturation in extremely preterm infants. N Engl J Med 362(21):1959–1969PubMedCentralCrossRefGoogle Scholar
  30. West JB (2000) Respiratory physiology-the essentials, 6th edn. Lippincott Williams & Wilkins, PhiladelphiaGoogle Scholar
  31. Yung D, Widlitz AC, Rosenzweig EB, Kerstein D, Maislin G, Barst RJ (2004) Outcomes in children with idiopathic pulmonary arterial hypertension. Circulation 110(6):660–665PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2015

Authors and Affiliations

  • Stacey Peterson-Carmichael
    • 1
    Email author
  • Ira Cheifetz
    • 1
  • Laurent Storme
    • 2
  1. 1.Division of Pediatric Critical Care MedicineDuke Children’s HospitalDurhamUSA
  2. 2.Pôle Femme Mère Nouveau-né / EA4489, Hôpital Jeanne de FlandreCHRU de Lille / Université Lille 2LilleFrance

Personalised recommendations